Disclaimer GHK-Cu (Copper Tripeptide-1) is supplied for research and educational purposes only
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Treatment allocation generated two total animal groups: semaglutide-treated (SEM, n=6), and control counterparts that received no drug (CON, n=10)
Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
Use a 0.3 mL syringe for best accuracy
Page, A